Try Claude
Lead FinderFind & enrich companies and people
AI Tools for Regulatory Consultants
AI tools that help regulatory consultants research compliance requirements, track enforcement actions, screen entities, and prepare regulatory submissions faster.
Get started for free
Works in Chat, Cowork and Code
ProductFirmViolation type
CardioSync Pacemaker 3400MedtronicSoftware defect — inappropriate therapy
AortiCath Balloon CatheterEdwards LifesciencesLabeling error — pressure range
HeartGuard ICD LeadBoston ScientificDesign defect — lead fracture risk
VascuFlow Stent SystemAbbottSterility assurance failure
8 total recalls found · 3 Class I (most serious)
Product recall and enforcement monitoring
Track FDA and CPSC product recalls and warning letters relevant to your clients' product categories. Monitor the competitive landscape for enforcement patterns and build proactive compliance strategies.
Show all FDA Class I recalls for medical devices in the Class II orthopedic implant category issued in the past 6 months. Include the 510(k) number, recall reason, and distribution scope.
Found 8 Class I recalls for orthopedic implants in the past 6 months. Top violations: sterility assurance failures (3), labeling errors (3), design defects (2). Average distribution scope: 12 states. Recall reasons and corrective action summaries attached.
ToolRouter search_recalls
ProductFirmViolation
OrthoMax Hip Stem 7000Zimmer BiometSterility assurance failure
NovaTorque Knee SystemSmith+NephewLabeling error — size indication
TitanHip Acetabular CupDePuy SynthesDesign defect — taper corrosion
8 total recalls · Avg distribution: 12 states
FDA drug labeling and regulatory reference
Look up current FDA-approved drug labeling to support regulatory submissions, label comparisons, and competitive intelligence on approved indications. Pull structured prescribing information on demand.
Pull the FDA-approved prescribing information for Ozempic (semaglutide). I need the approved indications, contraindications, most important warnings, and approved dosing schedule.
Ozempic (semaglutide): Approved for type 2 diabetes management (2017) and CV risk reduction (2020). Contraindicated in personal/family history of MTC, MEN 2 syndrome. Black box warning: thyroid C-cell tumors. Dosing: 0.5mg weekly for 4 weeks, then 1mg weekly; max 2mg weekly. Full label extracted.
ToolRouter get_drug_info
Approved indications
T2DM management (2017) + CV risk reduction (2020)
Contraindications
Personal/family history of MTC or MEN 2 syndrome
Black box warning
Thyroid C-cell tumors in rodents — unknown human risk
Dosing (standard)
0.5mg/wk for 4 wks → 1mg/wk; max 2mg/wk
Post-market commitment
Ongoing CV outcomes study SUSTAIN-6 data submitted
Clinical trial landscape research
Research the clinical trial pipeline for a therapeutic area before an FDA submission or competitive analysis. Map active, recruiting, and completed trials by phase, sponsor, and endpoint.
Find all Phase 3 clinical trials for non-alcoholic steatohepatitis (NASH) that are currently recruiting or active. Include NCT number, sponsor, primary endpoint, and estimated completion.
Found 11 active/recruiting Phase 3 NASH trials. Lead sponsors: Madrigal Pharmaceuticals, Gilead Sciences, Novo Nordisk, Intercept. Primary endpoints: NASH resolution without worsening fibrosis (7 trials), liver fibrosis improvement (4). Earliest estimated completion: Q4 2025.
ToolRouter search_trials
Nct numberSponsorPrimary endpoint
NCT04822584Madrigal PharmaceuticalsNASH resolution without worsening fibrosis
NCT05004493Gilead SciencesLiver fibrosis improvement ≥1 stage
NCT05095064Novo NordiskNASH resolution without worsening fibrosis
11 active/recruiting Phase 3 NASH trials
Regulatory intelligence and compliance research
Research evolving regulatory requirements across FDA, EMA, ICH, and international health authority guidance. Track changes to GMP, GCP, and GLP guidelines that affect client operations.
Summarize the key changes in ICH Q12 (Pharmaceutical Product Lifecycle Management) and explain what post-approval change management protocols (PACMPs) pharmaceutical manufacturers need to have in place by 2025.
ICH Q12 finalized 2020, now implemented by FDA (2024 guidance), EMA, and Health Canada. Key: companies must establish PACMP in marketing applications for established conditions vs. post-approval changes. FDA issued draft guidance clarifying 3 tiers. CMC changes previously requiring PAS submissions may qualify for CBE-0 under approved PACMP.
ToolRouter research
Final guideline
ICH Q12 finalized 2020 · implemented by FDA, EMA, Health Canada
Key concept
Established Conditions (EC) must be defined in marketing applications
PACMP requirement
Post-Approval Change Management Protocol required for each EC
FDA tier impact
CMC changes previously requiring PAS may qualify for CBE-0 under PACMP
FDA guidance
Draft guidance issued 2024 — 3-tier change classification system
ToolRouter search_news
DateSourceHeadline
Mar 18, 2026FDADraft guidance on ICH Q12 PACMP implementation opens for comment
Feb 12, 2026EMAEMA Q&A document on ICH Q12 established conditions published
Jan 9, 2026Health CanadaPACE program expanded to cover biologics under ICH Q12 framework
Regulatory compliance client prospecting
Find Regulatory Affairs and Compliance leaders at life sciences, medical device, and financial services companies. Target prospects with upcoming product launches or recent enforcement history.
Find Head of Regulatory Affairs and VP Regulatory Strategy roles at US pharmaceutical companies with at least one product in Phase 3 trials or pending NDA/BLA submission.
Found 58 regulatory leaders at pharma companies with active late-stage pipelines. 23 at companies with NDA/BLA filings pending at FDA this year — strong timing for regulatory consulting outreach. Includes name, title, company, and LinkedIn.
ToolRouter find_leads
NameTitleCompany
Dr. Priya SharmaVP Regulatory AffairsArcus Biosciences
James WhitfieldChief Compliance OfficerNovaBay Pharma
Lauren KimDirector Regulatory AffairsNuvation Bio
Tom GallagherVP Regulatory StrategyInhibrx
58 regulatory leaders · 23 with pending NDA/BLA filings
Ready-to-use prompts
FDA recall search
Search FDA recalls for dietary supplement products with contamination violations in the past 18 months. Show product name, company, violation type, and distribution scope.
Drug label lookup
Pull FDA prescribing information for adalimumab (Humira). Extract approved indications, contraindications, REMS requirements, and biosimilar interchangeability status.
Clinical trial search
Find recruiting Phase 2 and Phase 3 clinical trials for Alzheimer's disease prevention in patients with early MCI. Include sponsor, intervention type, and enrollment target.
GDPR enforcement research
Summarize the top 10 GDPR enforcement actions by fine amount in 2024. Include the supervisory authority, company, violation type, and key compliance failures.
Find compliance officer prospects
Find Chief Compliance Officers and VP Regulatory Affairs at US medical device companies with FDA 510(k) or PMA approvals. Include company, title, and LinkedIn profile.
ICH guideline research
Summarize the key requirements of ICH E6(R3) GCP guidelines for clinical trial data integrity, electronic source data, and risk-based quality management. Compare to E6(R2).
Competitor regulatory timeline
Research the regulatory approval history and pipeline for Novo Nordisk's GLP-1 portfolio. What NDA/BLA submissions are pending, and what post-market commitments have been issued?
Country regulatory requirements
Compare medical device registration requirements in Japan (PMDA), South Korea (MFDS), Australia (TGA), and Brazil (ANVISA) for a Class II diagnostic device. Include timeline, fees, and clinical data requirements.
Tools to power your best work
Deep ResearchAI research reports with citations
Drug InformationDrug info: recalls & side effects
Product RecallsFood, drug, and product recalls
Regulatory ActionsSEC, CFPB, FDIC & Federal Register
Compliance ScreeningAML, sanctions, PEP & due diligence investigations
Clinical TrialsClinical trials & drug safety data
NewsSearch and track news worldwide
165+ tools.
One conversation.
Everything regulatory consultants need from AI, connected to the assistant you already use. No extra apps, no switching tabs.
Pre-submission regulatory intelligence
Before preparing an FDA submission, research the regulatory pathway, comparable approvals, and current agency guidance to define the strategy.
Regulatory risk assessment for M&A
Assess the regulatory risk profile of an acquisition target in life sciences — recall history, enforcement exposure, and pipeline regulatory status.
Regulatory change monitoring report
Produce a monthly regulatory intelligence digest for clients covering new guidance, enforcement trends, and changes affecting their product categories.
Frequently Asked Questions
What regulatory agencies and jurisdictions are covered?
Regulatory Actions covers US financial regulators (SEC, FINRA, OCC, CFPB, CFTC). Product Recalls covers FDA (food, drug, device, cosmetics) and CPSC. Drug Information covers FDA-approved prescription drug labeling. Deep Research can surface guidance from EMA, PMDA, Health Canada, and other international health authorities.
Can clinical trials data support FDA submission preparation?
Clinical Trials searches ClinicalTrials.gov for active, recruiting, and completed trials by condition, intervention, and sponsor. This is useful for competitive landscape analyses, establishing unmet medical need, and identifying predicate devices or comparable drugs for regulatory strategy.
How current is the FDA drug labeling information?
Drug Information pulls from the FDA's official drug labeling database (DailyMed) which reflects the most recently approved prescribing information. This is suitable for label comparisons, indication research, and reference in regulatory strategy documents.
Can these tools support EU regulatory requirements like CE marking?
Deep Research can synthesize EU MDR/IVDR requirements, IVDR transition timelines, and notified body guidance. For EU-specific enforcement and regulatory decisions, combine with regulatory news monitoring. Country Data provides useful context on EU member state implementation approaches.
How can I find pharmaceutical clients who need regulatory support urgently?
Lead Finder targets regulatory affairs leaders at companies with active IND/NDA/BLA filings or pipeline products in late-stage development. Combine with Product Recalls to identify companies with recent enforcement exposure — both groups have strong near-term needs for regulatory consulting.
Give your AI superpowers.
Get started for free
Works in Chat, Cowork and Code